Novo Nordisk faces US Senate inquiry over weight loss drug prices
王俊杰2017
发表于 2024-9-23 14:21:44
201
0
0
According to the website of the United States Senate, the Senate will hold a hearing on September 24 local time to examine whether Novo Nordisk provides overpriced smeglutide products Ozempic and Wegovy for patients with diabetes and obesity.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Tianfeng International analyst Guo Mingchi: Apple's affordable Vision Pro production has been postponed until after 2027
- Nvidia agrees to TSMC raise 3nm and CoWoS prices
- Novo Nordisk has participated in the CIIE for seven consecutive years, working together with various sectors to promote the concept of "healthy metabolism"
- Novo Nordisk warns of the risk of compound generic semaglutide, which has caused 10 deaths and 100 hospitalizations
- Lai Lai scares, Novo Nordisk saves the scene! The market prospects of weight loss drugs still make many players salivate
- Bitcoin price once hit a new historical high of $95000
- 1 Bitcoin ≥ 100000 USD! Reviewing the Path of Bitcoin Price Soaring
- Novo Nordisk: All regulatory delivery conditions for Novo Nordisk's $16.5 billion acquisition of Contante have been met
- Novo Nordisk invests 8.5 billion Danish kroner to build new production facility in Odense, Denmark
- Novo Nordisk's pre-market decline narrows to 20%
